is retatrutide available Today we shared new results on retatrutide, an investigational, first-of-its-kind Retatrutide, a new weight loss
Description
See how we grade evidence
Novo Nordisk's oral version of its obesity injection Wegovy could enter the market by year-end, while Eli Lilly's pill orforglipron could launch next year

Triple Receptor Agonism Published research has characterized retatrutide's activity at three distinct receptors: GIP, GLP-1, and glucagon receptors

2023 (retatrutide Phase 2) is the retatrutide reference

Intestinal release of GLP-1 augments initial insulin secretion in vivo in part through a vagal-vagal reflex leading to cholinergic stimulation of islet beta cells

Characteristics of GLP-1RAs GLP-1 receptor agonists (GLP-1RAs) have transformed the management of type 2 diabetes and obesity
